Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NMRA

Neumora Therapeutics (NMRA)

Neumora Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NMRA
DateTimeSourceHeadlineSymbolCompany
06/14/20244:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
06/14/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
05/14/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar DepressionNASDAQ:NMRANeumora Therapeutics Inc
05/07/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NMRANeumora Therapeutics Inc
05/07/20247:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
05/07/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
05/06/20247:00AMGlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in MayNASDAQ:NMRANeumora Therapeutics Inc
04/15/20246:30AMGlobeNewswire Inc.Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyNASDAQ:NMRANeumora Therapeutics Inc
03/13/20247:00AMGlobeNewswire Inc.Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS DaysNASDAQ:NMRANeumora Therapeutics Inc
03/07/20244:34PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NMRANeumora Therapeutics Inc
03/07/20247:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
03/07/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
02/16/20244:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
02/16/20244:19PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
02/16/20244:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
02/16/20244:13PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NMRANeumora Therapeutics Inc
01/22/20247:00AMGlobeNewswire Inc.Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial OfficerNASDAQ:NMRANeumora Therapeutics Inc
01/08/20248:32AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
01/02/20247:00AMGlobeNewswire Inc.Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NMRANeumora Therapeutics Inc
12/15/20235:06PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NMRANeumora Therapeutics Inc
12/12/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Appoints Jason Duncan as Chief Legal OfficerNASDAQ:NMRANeumora Therapeutics Inc
11/28/20234:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
11/27/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical StudyNASDAQ:NMRANeumora Therapeutics Inc
11/01/20234:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NMRANeumora Therapeutics Inc
11/01/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NMRANeumora Therapeutics Inc
11/01/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NMRANeumora Therapeutics Inc
10/30/20237:00AMGlobeNewswire Inc.Neumora Therapeutics to Participate in Upcoming Conferences in NovemberNASDAQ:NMRANeumora Therapeutics Inc
10/10/20237:00AMGlobeNewswire Inc.Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and DevelopmentNASDAQ:NMRANeumora Therapeutics Inc
09/19/20236:51PMKR Market News인스타카트, 나스닥 데뷔로 주가는 12% 상승NASDAQ:NMRANeumora Therapeutics Inc
09/14/20238:49PMGlobeNewswire Inc.Neumora Therapeutics Announces Pricing of Initial Public OfferingNASDAQ:NMRANeumora Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NMRA